A lymphatic-absorbed multi-targeted kinase inhibitor for myelofibrosis therapy

Activation of compensatory signaling nodes in cancer often requires combination therapies that are frequently plagued by dose-limiting toxicities. Intestinal lymphatic drug absorption is seldom explored, although reduced toxicity and sustained drug levels would be anticipated to improve systemic bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Ross, Brian D., Jang, Youngsoon, Welton, Amanda, Bonham, Christopher A., Palagama, Dilrukshika S. W., Heist, Kevin, Boppisetti, Jagadish, Imaduwage, Kasun P., Robison, Tanner, King, Leah R., Zhang, Edward Z., Amirfazli, Cyrus, Luker, Kathryn E., Lee, Winston Y., Luker, Gary D., Chenevert, Thomas L., Van Dort, Marcian E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386018/
https://www.ncbi.nlm.nih.gov/pubmed/35977945
http://dx.doi.org/10.1038/s41467-022-32486-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386018/
https://www.ncbi.nlm.nih.gov/pubmed/35977945
http://dx.doi.org/10.1038/s41467-022-32486-8

Ejemplares similares